| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 3,151 | 3,272 | 3,324 | 3,450 | 3,710 | 3,728 | 3,742 | 3,871 | 3,625 | 3,645 | 4,366 | 4,302 | 4,033 | 4,226 | 4,694 | 5,242 | 5,234 | 5,377 | 5,539 | 5,830 | 6,108 | 5,951 | 6,432 | 9,300 | 6,071 | 5,802 | 5,987 | 6,089 | 5,844 | 6,218 | 5,731 | 6,481 | 6,514 | 6,907 | 7,339 | 7,434 | 7,628 | 7,679 | 7,783 | 8,052 | 8,516 | 7,899 | 8,359 | 8,793 |
| Expenses | 2,506 | 2,574 | 2,586 | 2,688 | 2,885 | 2,878 | 2,847 | 3,011 | 2,920 | 2,845 | 3,319 | 3,311 | 3,261 | 3,539 | 3,792 | 4,208 | 4,271 | 4,311 | 4,473 | 4,701 | 4,862 | 4,679 | 5,071 | 5,011 | 4,735 | 4,502 | 4,766 | 4,993 | 5,002 | 5,303 | 4,950 | 5,453 | 5,477 | 5,772 | 5,846 | 5,753 | 6,042 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,938 |
| EBITDA | 645 | 698 | 738 | 762 | 825 | 851 | 895 | 860 | 704 | 800 | 1,047 | 992 | 772 | 687 | 902 | 1,033 | 963 | 1,066 | 1,066 | 1,130 | 1,247 | 1,271 | 1,361 | 4,290 | 1,335 | 1,300 | 1,220 | 1,096 | 842 | 914 | 781 | 1,027 | 1,037 | 1,135 | 1,493 | 1,681 | 1,585 | 1,730 | 1,553 | 1,652 | 1,894 | 1,634 | 1,752 | 1,855 |
| Operating Profit % | 20 % | 21 % | 22 % | 22 % | 21 % | 22 % | 23 % | 22 % | 18 % | 21 % | 24 % | 22 % | 18 % | 15 % | 19 % | 19 % | 18 % | 20 % | 19 % | 19 % | 20 % | 20 % | 20 % | 21 % | 21 % | 21 % | 19 % | 17 % | 14 % | 14 % | 13 % | 15 % | 14 % | 15 % | 18 % | 21 % | 19 % | 20 % | 19 % | 19 % | 21 % | 20 % | 20 % | 19 % |
| Depreciation | 85 | 89 | 93 | 99 | 111 | 106 | 110 | 111 | 100 | 131 | 132 | 138 | 157 | 155 | 164 | 163 | 187 | 241 | 243 | 250 | 232 | 256 | 257 | 277 | 266 | 280 | 294 | 299 | 254 | 280 | 298 | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 |
| Interest | 21 | 31 | 68 | 9 | 25 | 21 | 18 | 14 | 14 | 17 | 17 | 19 | 25 | 30 | 35 | 48 | 50 | 50 | 41 | 37 | 32 | 21 | 16 | 20 | 18 | 13 | 10 | 16 | 9 | 15 | 25 | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 119 | 115 | 98 | 95 | 93 |
| Profit Before Tax | 557 | 634 | 631 | 717 | 761 | 786 | 830 | 796 | 649 | 709 | 979 | 902 | 651 | 571 | 787 | 917 | 816 | 863 | 864 | 938 | 1,078 | 1,084 | 1,193 | 4,005 | 1,061 | 1,018 | 968 | 794 | 594 | 679 | 523 | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,208 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 |
| Tax | 153 | 162 | 178 | 173 | 206 | 201 | 224 | 218 | 117 | 191 | 198 | 307 | 122 | 116 | 175 | 205 | 231 | 228 | 224 | 233 | 229 | 301 | 386 | 1,058 | 260 | 248 | 271 | 190 | 18 | 159 | 113 | 189 | 224 | 242 | 324 | 323 | 323 | 406 | 391 | 354 | 432 | 383 | 428 | 429 |
| Net Profit | 403 | 472 | 453 | 545 | 555 | 585 | 606 | 579 | 532 | 518 | 781 | 595 | 529 | 456 | 611 | 712 | 585 | 636 | 640 | 705 | 849 | 783 | 807 | 2,948 | 801 | 770 | 697 | 604 | 576 | 520 | 410 | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 |
| EPS in ₹ | 13.84 | 16.18 | 7.77 | 9.32 | 9.49 | 9.99 | 10.41 | 9.88 | 9.10 | 8.85 | 13.33 | 10.16 | 9.02 | 7.78 | 10.44 | 12.15 | 9.99 | 10.85 | 10.92 | 12.04 | 14.50 | 13.32 | 13.78 | 50.31 | 13.67 | 13.14 | 11.89 | 10.32 | 9.84 | 8.88 | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 |
Aurobindo Pharma
Aurobindo Pharma
1,285.00
+5.40
(0.42%)
Market Cap
74,633.01 Cr
PE Ratio
21.32
Volume
2,15,005.00
Day High - Low
1,295.00 - 1,275.10
52W High-Low
1,319.80 - 1,010.00
Key Fundamentals
Market Cap
74,633.01 Cr
EPS
59.81
PE Ratio
21.32
PB Ratio
2.12
Book Value
603.32
EBITDA
7,204.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
10.67
Debt to Equity
0.24
Analyst Rating and Forecast
- By Refinitiv from26 analysts
Actual
Company News
View All News
Principal Commissioner confirms Rs. 77.61 crore GST demand against Aurobindo Pharma for excess IGST refunds and non-compliance issues during 2017-2020. Company plans tribunal appeal.
APL Healthcare's Unit-IV receives VAI classification from US FDA after December inspection. Five issues noted during facility review, inspection concluded successfully.
Aurobindo Pharma's subsidiary Eugia Pharma introduces pomalidomide capsules in the US market as a generic version of Pomalyst®, targeting a $3.3 billion market opportunity.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,788.40 | #1 4,29,097.07 | 39.05 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 56.64 | |
6,119.50 | 1,62,453.50 | 65.06 | 9,712.00 | 18.67 | 2,191 | -1.02 | 38.37 | |
4,277.50 | 1,44,770.04 | 63.50 | 11,539.40 | 6.99 | 1,911 | 26.24 | 49.65 | |
1,279.40 | 1,06,782.61 | 19.27 | 33,741.20 | 16.73 | 5,725 | -15.28 | 47.81 | |
2,305.60 | 1,05,319.53 | 22.42 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 53.17 | |
1,292.10 | 1,04,372.19 | 23.14 | 28,409.50 | 7.12 | 5,291 | -57.18 | 36.50 | |
898.30 | 90,390.00 | #1 17.74 | 23,511.00 | 18.55 | 4,615 | -0.32 | 42.14 | |
2,083.60 | 86,012.06 | 47.89 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 43.63 | |
1,285.00 | #9 74,633.01 | #3 21.32 | #3 32,345.60 | #7 9.43 | #5 3,484 | #5 7.59 | 61.70 | |
5,325.00 | 63,668.36 | 26.27 | 13,458.30 | 3.70 | 2,216 | 1.90 | 39.37 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
9.43 %
Net Income Growth
9.93 %
Cash Flow Change
61.21 %
ROE
0.47 %
ROCE
10.77 %
EBITDA Margin (Avg.)
2.86 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 |
| Fixed Assets | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,397 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 |
| Current Assets | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,123 | 21,460 | 23,772 | 27,163 |
| Capital Work in Progress | 420 | 848 | 1,458 | 1,583 | 1,669 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 |
| Other Assets | 8,770 | 10,769 | 9,712 | 12,686 | 15,951 | 16,991 | 20,828 | 18,645 | 22,934 | 26,338 | 29,839 |
| Total Equity & Liabilities | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 |
| Current Liabilities | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 11,494 | 12,199 | 14,682 |
| Non Current Liabilities | 1,596 | 790 | 270 | 753 | 541 | 718 | 1,260 | 1,192 | 1,544 | 3,022 | 2,456 |
| Total Equity | 5,182 | 7,290 | 9,374 | 11,682 | 13,892 | 16,825 | 21,929 | 24,574 | 26,852 | 29,851 | 32,647 |
| Reserve & Surplus | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 |
| Share Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 |
| Investing Activities | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 |
| Operating Activities | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,017 | 2,387 | 2,435 | 3,925 |
| Financing Activities | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 51.94 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.80 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 18.02 % | 16.73 % | 16.59 % | 16.29 % | 15.33 % | 14.37 % | 14.21 % | 13.94 % |
| DIIs | 10.99 % | 12.72 % | 13.82 % | 15.11 % | 15.83 % | 15.58 % | 16.23 % | 14.89 % | 15.08 % | 15.73 % | 17.94 % | 20.23 % | 23.28 % | 24.77 % | 25.13 % | 25.20 % | 26.23 % | 26.93 % | 27.60 % | 27.68 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.71 % | 8.54 % | 9.60 % | 8.99 % | 8.37 % | 8.80 % | 8.65 % | 9.42 % | 8.54 % | 7.01 % | 6.15 % | 5.64 % | 5.52 % | 5.47 % | 5.33 % | 5.52 % | 5.47 % | 5.67 % | 5.25 % | 5.36 % |
| Others | 28.36 % | 26.91 % | 24.74 % | 24.07 % | 23.97 % | 23.79 % | 23.29 % | 23.85 % | 24.54 % | 25.42 % | 24.07 % | 22.29 % | 1.36 % | 1.23 % | 1.13 % | 1.17 % | 1.15 % | 1.20 % | 1.13 % | 1.19 % |
| No of Share Holders | 2,32,634 | 2,43,315 | 3,29,940 | 3,41,568 | 3,38,639 | 3,59,684 | 3,58,459 | 3,69,828 | 3,43,617 | 2,93,214 | 2,59,638 | 2,41,944 | 2,44,575 | 2,38,622 | 2,48,488 | 2,57,962 | 2,69,323 | 2,72,208 | 2,47,662 | 2,36,859 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3.2 | 2.5 | 2.5 | 3 | 4 | 9 | 7.5 | 4.5 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.57 | 0.32 | 0.61 | 0.34 | 0.6 | 1.77 | 0.69 | 0.39 | 0.00 | 0.00 |
Announcements
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
3 days ago
3 days agoClassification Of Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company As VAI By The US FDA - Reg.5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2026
Mar 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Mar 02, 2026Clarification On Media Report Aurobindo PharmaS P Sarath Chandra Reddy Acquitted In Delhi Liquor Scam Case.
Mar 02, 2026
Mar 02, 2026Clarification sought from Aurobindo Pharma LtdFeb 27, 2026
Feb 27, 2026Completion Of US FDA Inspection At Unit I Of Eugia Pharma Specialities LtdFeb 27, 2026
Feb 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-AcquisitionFeb 24, 2026
Feb 24, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2026
Feb 24, 2026Intimation Of Orders Passed By The Goods & Services Tax DepartmentFeb 19, 2026
Feb 19, 2026Clarification On News Item Appearing In Https://Www.Ndtvprofit.Com/"Feb 18, 2026
Feb 18, 2026Clarification sought from Aurobindo Pharma LtdFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2026
Feb 11, 2026Completion Of US FDA Inspection At Unit-VII Of Aurobindo Pharma Limited JedcherlaFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-RestructuringFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-AcquisitionFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Feb 09, 2026Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for Outcome Of Board MeetingFeb 09, 2026
Feb 09, 2026Completion Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd. A Wholly Owned Subsidiary Of The CompanyFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2026
Feb 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Feb 02, 2026Clarification On Significant Volume Movement In CompanyS SharesFeb 02, 2026
Feb 02, 2026Clarification sought from Aurobindo Pharma LtdFeb 01, 2026
Feb 01, 2026Clarification On Significant Volume Movement In CompanyS SharesJan 31, 2026
Jan 31, 2026Board Meeting Intimation for Intimation Of Board Meeting DateJan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-AcquisitionJan 23, 2026
Jan 23, 2026Curateq Biologics Receives NOC From Health Canada For Its Biosimilar DyrupegJan 09, 2026
Jan 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Jan 05, 2026Announcement under Regulation 30 (LODR)-AcquisitionJan 01, 2026
Jan 01, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 30, 2025
Dec 30, 2025Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company Has Mutually Agreed To Terminate Its Agreement With Biofactura Inc USADec 27, 2025
Dec 27, 2025Closure of Trading WindowDec 24, 2025
Dec 24, 2025Announcement under Regulation 30 (LODR)-AcquisitionDec 23, 2025
Dec 23, 2025Completion Of US FDA Inspection At Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The CompanyDec 18, 2025
Dec 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 15, 2025
Dec 15, 2025Completion Of US FDA Inspection At Unit-V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The CompanyDec 12, 2025
Dec 12, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 61.70
ATR(14)
Volatile 39.29
STOCH(9,6)
Overbought 88.40
STOCH RSI(14)
Overbought 80.66
MACD(12,26)
Bullish 9.47
ADX(14)
Weak Trend 15.90
UO(9)
Bearish 63.17
ROC(12)
Uptrend But Slowing Down 5.62
WillR(14)
Neutral -22.87
About Aurobindo Pharma
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Website
Chairperson NameM R Kumar
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
